The Side-Effect Profiles of Antipsychotic Medications

Primary Psychiatry

Volumn 10, Issue 8, 2003, Pages 78-91

  Zajecka, John ^a,b,c   Goldstein, Corey ^a,b  

^a Department of Psychiatry ^*  (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c RUSH NORTH SHORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; BETHANECHOL; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIAZEPAM; DIPHENHYDRAMINE; FLUPHENAZINE; HALOPERIDOL; LAXATIVE; LORAZEPAM; LOXAPINE; LOXAPINE SUCCINATE; MESORIDAZINE; MESORIDAZINE BESYLATE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; UNINDEXED DRUG; ZIPRASIDONE;

ACCOMMODATION PARALYSIS; AKATHISIA; AMENORRHEA; ANTICHOLINERGIC EFFECT; ATRIOVENTRICULAR BLOCK; AUTONOMIC DYSFUNCTION; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CONSTIPATION; DIABETES MELLITUS; DROWSINESS; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; EJACULATION DISORDER; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERPROLACTINEMIA; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INTRAOCULAR HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; LACTATION DISORDER; LIVER TOXICITY; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTOXICITY; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PSYCHOPHARMACOLOGY; PSYCHOSIS; QT PROLONGATION; QTC PROLONGATION; RASH; RECEPTOR BLOCKING; REVIEW; SEDATION; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TACHYCARDIA; TARDIVE DYSKINESIA; URINE RETENTION; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

EID: 1842559297     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Nemeroff CB. Safety of available agents used to treat bipolar disorder: focus on weight gain. J Clin Psychiatry. 2003;64:532-539.
2. Keskiner A, el-Toumi A, Bousquet T. Psychotropic drugs, diabetes, and chronic mental patients. Psychosomatics. 1973;14:176-181.
3. McKee HA, D'Arcy PF, Wilson PJ. Diabetes and schizophrenia-a preliminary study. J Clin Hosp Pharm. 1986;11:297-299.
4. Mukherjee S, Mahadik SP. A new paradigm for schizophrenia? Schizop Res. 1994;12:191-194.
5. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitis in schizophrenic patients. Compr Psychiatry. 1996;37:68-73.
6. Cassidy F, Ahearn E, Carrol BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry. 1999;156:1417-1420.
7. Charatan FBE, Bartlett NG. The effect of chlorpromazine on glucose tolerance. J Ment Sci. 1955;101:351-353.
8. Kwong K, Cavazzoni P, Hornbuckel K, et al. Higher incidence of diabetes mellitus during exposure to antipsychotics - findings from a retrospective cohort study in the United States. Poster presented at: 41st Annual Meeting of the New Clinical Drug Evaluation Unit; May 2001; Phoenix, Az.
9. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marer Se, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63:856-865.
10. Gianfrancesco F, Grogg A, Ramy M, Nasrallah H. Association of newly reported diabetes and antipsychotics in psychosis patients: findings from a large health plan database. Poster presented at: 41st New Clinical Drug Evaluation Unit; May 2001; Phoenix, Az.
11. Masand P, Gupta S. Long-term effects of antipsychotics. J Psychiatric Practice. 2000;6:299-309.
12. Zajecka JM. Solutions to the everyday challenges in managing patients on psychotropic medications. Slides presented at: 154th Annual Meeting of the American Psychiatric Association; May 2001; New Orleans, LA.
13. Schatzberg AF, DeBattista C. The Black Book of Psychotropic Dosing and Monitoring 2003. New York, NY: MBL Communcations, Inc.; 2003.
14. Bezchlibnyk-Butler KZ, Jefferies JJ. Antipsychotics. Clinical Handbook of Psychotropic Drugs. 12th ed. Hogrefe and Huber Publishers: Gottinghen, Bern; 2002:65-101.
15. Janicak PG, Davis JM, Preskorn SH, Ayd FJ. Treatment with antipsychotics. Principles and Practice of Psychopharmacotherapies. 3rd ed. Williams and Wilkins: Philadelphia, Penn; 2001:100-188.
16. Abilify [package insert]. Bristol-Myers Squibb, Otsuka Pharmaceuticals. 2003.
17. American Medical Association: AMA Drug Evaluations: Annual 1992. American Medical Association: Chicago, Ill; 1992.
18. Sadock BJ, Kaplan HI. Schizophrenia. Comprehensive Textbook of Psychiatry. 7th ed. New York, NY: Lippincott, Williams, & Wilkins; New York; 2000:1096-1169.
19. Mokdad AH, Serdula MK, Dietz WA, Bowman BA, Marks JS, Koplan JP. The continuing epidemic of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
20. Anonymous. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1197.
21. Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry. 2002;63(suppl 4):56-62.
22. Dixon R, Kinan BJ, Liu H, Ahl J. Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels. Poster presented at: the Annual Meeting of the American College of Neuropsychopharmacology; December 2002; Puerto Rico.
23. Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry. 1999;57(suppl 11):40-45,46-52.
24. Zajecka JM. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry. 2000;61:20-25.
25. Diagnostic and Statistical Manual of Mental Disorders. 4th ed Washington, DC: American Psychiatric Assocation Press; 1994.
26. Gupta S, Franl B, Madhusoodanan S. Tardive dyskinesia: legal issues and consent. Psychiatric Ann. 2002;32:245-248.